{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T01:41:36Z","timestamp":1755826896657,"version":"3.44.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,20]]},"DOI":"10.7759\/cureus.90634","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T06:54:43Z","timestamp":1755759283000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment Outcomes of HER2-Directed Therapy in Patients With HER2-Positive Non-metastatic Breast Cancer in Low-Resource Settings"],"prefix":"10.7759","author":[{"given":"Maryam","family":"Imran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Awais","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameen","family":"Bin Naeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ahsan","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minahil","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amna","family":"Karim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aftab","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehar","family":"Bano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beenish","family":"Aqib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Abdullah Javaid Bukhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. Breast cancer. (2024). Accessed: July 25, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68:394-424. 10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl S","year":"2017","unstructured":"Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017, 389:2415-29. 10.1016\/S0140-6736(16)32417-5","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071987","article-title":"Emerging targeted therapies for HER2-positive breast cancer","volume":"15","author":"Mercogliano MF","year":"2023","unstructured":"Mercogliano MF, Bruni S, Mauro FL, Schillaci R. Emerging targeted therapies for HER2-positive breast cancer. Cancers (Basel). 2023, 15:1987. 10.3390\/cancers15071987","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomized trial","volume":"17","author":"Gianni L","year":"2016","unstructured":"Gianni L, Pienkowski T, Im YH, et al.. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomized trial. Lancet Oncol. 2016, 17:791-800. 10.1016\/S1470-2045(16)00163-7","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104305","article-title":"Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low\/positive advanced breast cancer: a meta-analysis of randomized controlled trials","volume":"196","author":"Ma R","year":"2024","unstructured":"Ma R, Shi Y, Yan R, Yin S, Bu H, Huang J. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low\/positive advanced breast cancer: a meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2024, 196:104305. 10.1016\/j.critrevonc.2024.104305","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain SM","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023, 22:101-26. 10.1038\/s41573-022-00579-0","journal-title":"Nat Rev Drug Discov"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.9189","article-title":"Structural barriers to diagnosis and treatment of cancer in low- and middle-income countries: the urgent need for scaling up","volume":"34","author":"Cazap E","year":"2016","unstructured":"Cazap E, Magrath I, Kingham TP, Elzawawy A. Structural barriers to diagnosis and treatment of cancer in low- and middle-income countries: the urgent need for scaling up. J Clin Oncol. 2016, 34:14-9. 10.1200\/JCO.2015.61.9189","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00132","article-title":"Challenges in access to new therapeutic agents: marginalized patients with cancer in Pakistan and the need for new guidelines","volume":"8","author":"Aziz Z","year":"2022","unstructured":"Aziz Z, Naseer H, Altaf A. Challenges in access to new therapeutic agents: marginalized patients with cancer in Pakistan and the need for new guidelines. JCO Glob Oncol. 2022, 8:e2100132. 10.1200\/GO.21.00132","journal-title":"JCO Glob Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.22034\/APJCP.2018.19.3.709","article-title":"Thirty years cancer incidence data for Lahore, Pakistan: trends and patterns 1984-2014","volume":"19","author":"Masood A","year":"2018","unstructured":"Masood A, Masood K, Hussain M, et al.. Thirty years cancer incidence data for Lahore, Pakistan: trends and patterns 1984-2014. Asian Pac J Cancer Prev. 2018, 19:709-17. 10.22034\/APJCP.2018.19.3.709","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2991\/jegh.k.230318.001","article-title":"Exploring the burden of cancer in Pakistan: an analysis of 2019 data","volume":"13","author":"Tufail M","year":"2023","unstructured":"Tufail M, Wu C. Exploring the burden of cancer in Pakistan: an analysis of 2019 data. J Epidemiol Glob Health. 2023, 13:129-138. 10.2991\/jegh.k.230318.001","journal-title":"J Epidemiol Glob Health"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036905","article-title":"Breast cancer: a review of risk factors and diagnosis","volume":"103","author":"Obeagu EI","year":"2024","unstructured":"Obeagu EI, Obeagu GU. Breast cancer: a review of risk factors and diagnosis. Medicine (Baltimore). 2024, 103:e36905. 10.1097\/MD.0000000000036905","journal-title":"Medicine (Baltimore)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S335934","article-title":"HER2-directed therapy in advanced breast cancer: benefits and risks","volume":"16","author":"Mand\u00f3 P","year":"2023","unstructured":"Mand\u00f3 P, Waisberg F, Pasquinelli R, Rivero S, Ostinelli A, Perazzo F. HER2-directed therapy in advanced breast cancer: benefits and risks. Onco Targets Ther. 2023, 16:115-32. 10.2147\/OTT.S335934","journal-title":"Onco Targets Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S69416","article-title":"Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer","volume":"6","author":"Stenehjem DD","year":"2014","unstructured":"Stenehjem DD, Yoo M, Unni SK, et al.. Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer. Breast Cancer (Dove Med Press). 2014, 6:169-77. 10.2147\/BCTT.S69416","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33102","article-title":"Novel HER2-targeted therapies for HER2-positive metastatic breast cancer","volume":"126","author":"Kunte S","year":"2020","unstructured":"Kunte S, Abraham J, Montero AJ. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer. 2020, 126:4278-88. 10.1002\/cncr.33102","journal-title":"Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00780-6","article-title":"The evolving landscape of HER2-directed breast cancer therapy","volume":"21","author":"Marti JL","year":"2020","unstructured":"Marti JL, Hyder T, Nasrazadani A, Brufsky AM. The evolving landscape of HER2-directed breast cancer therapy. Curr Treat Options Oncol. 2020, 21:82. 10.1007\/s11864-020-00780-6","journal-title":"Curr Treat Options Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomized, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz SA","year":"2018","unstructured":"Hurvitz SA, Martin M, Symmans WF, et al.. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomized, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018, 19:115-26. 10.1016\/S1470-2045(17)30716-7","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0556-7","article-title":"Pertuzumab for the neoadjuvant treatment of early-stage HER2-positive breast cancer: an evidence review group perspective of a NICE single technology appraisal","volume":"36","author":"Squires H","year":"2018","unstructured":"Squires H, Pandor A, Thokala P, et al.. Pertuzumab for the neoadjuvant treatment of early-stage HER2-positive breast cancer: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018, 36:29-38. 10.1007\/s40273-017-0556-7","journal-title":"Pharmacoeconomics"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron D","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, et al.. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017, 389:1195-205. 10.1016\/S0140-6736(16)32616-2","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13\u2008864 women in seven randomised trials","volume":"22","author":"Early Breast Cancer Trialists\u2019 Collaborative group (EBCTCG)","year":"2021","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13\u2008864 women in seven randomised trials. Lancet Oncol. 2021, 22:1139-50. 10.1016\/S1470-2045(21)00288-6","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/389591-treatment-outcomes-of-her2-directed-therapy-in-patients-with-her2-positive-non-metastatic-breast-cancer-in-low-resource-settings","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T06:54:45Z","timestamp":1755759285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/389591-treatment-outcomes-of-her2-directed-therapy-in-patients-with-her2-positive-non-metastatic-breast-cancer-in-low-resource-settings"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.90634","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}